P&G Partners With Rhinostics for Swabs

 My former employer innovates in COVID Testing

P&G Partners With Rhinostics to Take Innovative Nasal Swab to Market to Improve Speed of COVID-19 Testing  Press Release in Business Wire,  January 22, 2021

iMFLUX, a subsidiary of P&G, developed a novel fully injection-molded polypropylene nasal swab under the company’s efforts to positively impact COVID-19 testing availability

Rhinostics is bringing innovation to improve sample collection while removing costs and time from COVID testing workflow with automated consumables

CINCINNATI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Procter & Gamble (P&G) is licensing its novel nasal swab to Rhinostics to launch and bring to the clinical laboratory market. P&G developed the swab as part of its commitment to help communities address supply shortages and to bring creative solutions to bear on the challenges facing laboratories and supply chains during the COVID-19 pandemic. The project was a collaboration between resources from P&G’s Personal Health Care business and iMFLUX, a subsidiary focused on mold design and process technology innovation for the plastics injection molding market. Swabs continue to be in short supply and are critical to fighting the COVID-19 pandemic. The companies believe the nasal swab’s unique features make it a better material choice for both PCR and antigen-based assays. These swabs reduce handling and lab processing cycle time and increase lab capacity as new home collection kits expand rapidly into the virus detection market.

“We are proud to see the P&G developed nasal swab come to market through Rhinostics efforts. When we began this program, our intention was simply to help relieve bottlenecks in COVID-19 swab supply and bring a novel collection device to bear on the problem,” said Mary Wagner, SVP at P&G and CEO of iMFLUX. .... '